Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP and President, Hematology | December 31, 2020 | January 06, 2021 |
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Director · President and CEO | February 24, 2026 | February 25, 2026 |
| Disc Medicine, Inc.IRON · Entity 2273 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date December 31, 2020 · Filed January 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 38,889 |
Ending reported balance
After 2020-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-31 · Exercise / conversion · Acquired 14,946 · Balance 46,549 F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Row 2 · 2020-12-31 · Tax withholding · Disposed 7,660 · Balance 38,889 F2: Shares withheld for payment of taxes upon vesting of awards. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2020-12-31 | Direct | 0 |
Reported balance
After 2020-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-31 · Exercise / conversion · Disposed 14,946 · Balance 0 F4: Each restricted stock unit converts into one share of common stock upon vesting. F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Indirect401(k) | 1,966 |
Reported balance
Holding disclosure · report date 2020-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,966 F3: Based on recent 401(k) plan statement. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.
F2: Shares withheld for payment of taxes upon vesting of awards.
F3: Based on recent 401(k) plan statement.
F4: Each restricted stock unit converts into one share of common stock upon vesting.
Cullinan Therapeutics, Inc.
Report date February 24, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 390,803 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Sale · Disposed 13,515 · Balance 390,803 F1: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Disc Medicine, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17 | Direct | 5,176 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 5,176 · Balance 5,176 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.18 · Expires 2027-01-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 6,563 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $124.06 · Expires 2027-05-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.41 · Expires 2027-07-31 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.97 · Expires 2027-10-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.26 · Expires 2028-01-29 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.13 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 10,548 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 10,548 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.43 · Expires 2028-10-29 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 10,549 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 1,563 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-20 · Disposition to issuer · Disposed 5,357 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-20 · Disposition to issuer · Disposed 3,348 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-11-20 · Disposition to issuer · Disposed 27,749 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was fully exercisable.
F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 20:54 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 5,176 | $0.00 Strike: $70.79 | $0.00 |
DisclosureSEC source: 0001193125-26-279690 · ownership.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,176 Underlying: Common Stock · 5,176 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 13,515 | $14.47 | $195,562.05 |
DisclosureSEC source: 0001193125-26-072001 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,803 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 16,381 | $13.62 | $223,109.22 |
DisclosureSEC source: 0001193125-26-064254 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,318 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 828,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059639 · ownership.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,000 Underlying: Common Stock · 828,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 9,922 | $10.01 | $99,319.22 |
DisclosureSEC source: 0001193125-25-335482 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,699 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 21:56 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $57.74 | $0.00 |
DisclosureSEC source: 0000950170-25-096357 · ownership.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-07-13 F1 · derivative.exercise_date: The shares underlying this option vest over three years, with one-third vesting on July 14, 2026 and the remainder vesting in substantially equal monthly installments over the following two years. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 12,529 | $8.53 | $106,872.37 |
DisclosureSEC source: 0000950170-25-029199 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,621 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000950170-25-025029 · ownership.xml · derivative · entry 2 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2035-02-19 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 180,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-025029 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,150 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,400 | $11.87 | $99,708.00 |
DisclosureSEC source: 0000950170-24-140856 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,150 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 320,000 | $0.00 Strike: $17.54 | $0.00 |
DisclosureSEC source: 0000950170-24-019462 · ownership.xml · derivative · entry 2 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2034-02-22 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-019462 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,550 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,272 | $9.24 | $39,473.28 |
DisclosureSEC source: 0000950170-23-073405 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,550 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 20:59 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 759 | $11.40 | $8,652.60 |
DisclosureSEC source: 0000950170-23-030805 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,822 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:36 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 707 | $9.15 | $6,469.05 |
DisclosureSEC source: 0000950170-23-023939 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,581 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| April 25, 2023 Filed Apr 26, 2023 20:23 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 716 | $10.59 | $7,582.44 |
DisclosureSEC source: 0000950170-23-014838 · ownership.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,288 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 706 | $10.51 | $7,420.06 |
DisclosureSEC source: 0000899243-23-009714 · doc4.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,004 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 22:06 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 211,000 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0000899243-23-006004 · doc4.xml · derivative · entry 2 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,000 Underlying: Common Stock · 211,000 shares Expires 2033-02-21 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 22:06 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 109,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006004 · doc4.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,710 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 22:04 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 1,620 | $10.90 | $17,658.00 |
DisclosureSEC source: 0000899243-22-025077 · doc4.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,710 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 20:33 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | PurchaseCommon Stock | 8,090 | $12.40 | $100,316.00 |
DisclosureSEC source: 0000899243-22-021346 · doc4.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,090 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.34 to $12.45. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 02:50 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantPerformance Stock Unit · Derivative | 215,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009841 · doc4.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2025-03-05 F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. The performance stock units vest upon the Issuer's common stock achieving a specified price per share. F1 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. The performance stock units vest upon the Issuer's common stock achieving a specified price per share. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 20:35 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 2,710,000 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0000899243-21-040774 · doc4.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,710,000 Underlying: Common Stock · 2,710,000 shares Expires 2031-10-17 F1 · derivative.exercise_date: The option represents a right to purchase a total of 2,710,000 shares of the Issuer's Common Stock, which shall vest on a pro-rated basis commencing on October 18, 2021, with 1/48 of the shares vesting on a monthly basis over four years, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:13 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 14,946 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000028 · wf-form4_160989560418282.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 14,946 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:13 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 7,660 | $62.03 | $475,149.80 |
DisclosureSEC source: 0000014272-21-000028 · wf-form4_160989560418282.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,889 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:13 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 14,946 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000028 · wf-form4_160989560418282.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:24 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 6,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000298 · wf-form4_160704504862220.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,782 Underlying: Common Stock, $0.10 par value · 6,594 shares Expires 2023-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:24 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,380 | $62.18 | $210,168.40 |
DisclosureSEC source: 0000014272-20-000298 · wf-form4_160704504862220.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,603 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:24 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000298 · wf-form4_160704504862220.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 4,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000275 · wf-form4_160443891475377.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 4,650 shares Expires 2020-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on October 30, 2018. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,291 | $58.45 | $133,908.95 |
DisclosureSEC source: 0000014272-20-000275 · wf-form4_160443891475377.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,389 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:28 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000275 · wf-form4_160443891475377.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in three equal annual installments beginning on October 30, 2018. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:49 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 2,908 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000162 · wf-form4_158871174702049.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,908 shares Expires 2020-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: The restricted stock unit vests in three equal installments beginning on May 1, 2018. F1 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on May 1, 2018. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:49 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,433 | $60.26 | $86,352.58 |
DisclosureSEC source: 0000014272-20-000162 · wf-form4_158871174702049.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,030 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:49 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,908 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000162 · wf-form4_158871174702049.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in three equal installments beginning on May 1, 2018. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:10 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 32,082 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000112 · wf-form4_158405103353946.xml · derivative · entry 2 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,082 Underlying: Common Stock, $0.10 par value · 32,082 shares Expires 2023-03-10 F3 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2023. F3 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:10 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 21,388 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000112 · wf-form4_158405103353946.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · EVP and President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,388 Underlying: Common Stock, $0.10 par value · 21,388 shares Expires 2024-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 17,204 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000088 · wf-form4_158328384746829.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,410 Underlying: Common Stock, $0.10 par value · 17,204 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: The restricted stock unit vests in three equal installments beginning on March 1, 2020. F1 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on March 1, 2020. F1 · derivative.expiration_date: The restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 8,473 | $59.06 | $500,415.38 |
DisclosureSEC source: 0000014272-20-000088 · wf-form4_158328384746829.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,555 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units awards. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 17,204 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000088 · wf-form4_158328384746829.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 01:48 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 2,076 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000078 · wf-form4_158104011239112.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,152 Underlying: Common Stock, $0.10 par value · 2,076 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: The restricted stock unit vests in three equal installments beginning on February 4, 2020. F1 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on February 4, 2020. F1 · derivative.expiration_date: The restricted stock unit vests in three equal installments beginning on February 4, 2020. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 01:48 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,071 | $64.29 | $68,854.59 |
DisclosureSEC source: 0000014272-20-000078 · wf-form4_158104011239112.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,824 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 01:48 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,076 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000078 · wf-form4_158104011239112.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in three equal installments beginning on February 4, 2020. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 26,376 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000238 · wf-form4_157549668296245.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,376 Underlying: Common Stock, $0.10 par value · 26,376 shares Expires 2023-12-02 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 6,562 | $0.00 Strike: $102.18 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 25 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,562 shares Expires 2026-10-31 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $114.69 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 24 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2026-08-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $104.97 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 23 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2026-05-02 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $100.80 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 22 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-02-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $114.08 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 21 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-11-09 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $132.56 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 20 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-07-27 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.